Hemostatic effects of fenofibrate in patients with mixed dyslipidemia and impaired fasting glucose

Pharmacological Reports

Volumn 62, Issue 6, 2010, Pages 1099-1107

  Krysiak, Robert ^a   Handzlik, Gabriela ^a   Okopieñ, Bogusław ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Factor VII; Fenofibrate; Fibrinogen; Impaired fasting glucose; Mixed dyslipidemia; Plasminogen activator inhibitor I

Indexed keywords

APOLIPOPROTEIN B; BLOOD CLOTTING FACTOR 7; FENOFIBRATE; FIBRINOGEN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; FEMALE; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; LIPID METABOLISM; MALE; TREATMENT DURATION;

EID: 79551475680     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(10)70372-8     Document Type: Article

References (27)

1. Avellone G, Di Garbo V, Cordova R, Piliego T, Raneli G, De Simone R, Bompiani GD: Improvement of fibrinolysis and plasma lipoprotein levels induced by gemfibrozil in hypertriglyceridemia. Blood Coagul Fibrinolysis, 1995, 6, 543-548.
2. Balakumar P, Rose M, Singh M: PPAR ligands: are they potential agents for cardiovascular disorders? Pharmacology, 2007, 80, 1-10.
3. Chruściel P, Goch A, Banach M, Mikhailidis DP, Rysz J, Goch JH: Circadian changes in the hemostatic system in healthy men and patients with cardiovascular diseases. Med Sci Monit, 2009, 15, RA203-RA208.
4. Duez H, Lefebvre B, Poulain P, Torra IP, Percevault F, Luc G, Peters JM et al.: Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation. Arterioscler Thromb Vasc Biol, 2005, 25, 585-591.
5. Idzior-Waluś B, Sieradzki J, Rostworowski W, Zdzienicka A, Kawalec E, Wojcik J, Zarnecki A, Blane G: Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X. Eur J Clin Invest, 2000, 30, 871-878.
6. Kannel WB: Overview of hemostatic factors involved in atherosclerotic cardiovascular disease. Lipids, 2005, 40, 1215-1220.
7. Keating GM, Croom KF: Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs, 2007, 67, 121-153.
8. Keating GM, Ormrod D: Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia. Drugs, 2002, 62, 1909-1944.
9. Kita T, Kume N, Minami M, Hayashida K, Murayama T, Sano H, Moriwaki H et al.: Role of oxidized LDL in atherosclerosis. Ann NY Acad Sci, 2001, 947, 199-205.
10. Krysiak R, Łabuzek K, Okopieñ B: Effect of atorvastatin and fenofibric acid on adipokine release from visceral and subcutaneous adipose tissue of patients with mixed dyslipidemia and normolipidemic subjects. Pharmacol Rep, 2009, 60, 1134-1145.
11. Krysiak R, Okopieñ B, Herman ZS: Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes. Drugs, 2003, 63, 1821-1854. (Pubitemid 37083030)
12. Krysiak R, Stachura-Kułach A, Okopieñ B: Metabolic and monocyte-suppressing action of fenofibrate in patients with mixed dyslipidemia and early glucose metabolism abnormalities. Pharmacol Rep, 2010, 62, 120-130.
13. Manninen V, Tenkanen L, Koskinen, Huttunen JK, Mänttäri M, Heinonen OP, Frick MH: Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation, 1992, 85, 37-45.
14. Neve BP, Corseaux D, Chinetti G, Zawadzki C, Fruchart JC, Duriez P, Staels B, Jude B: PPARα agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation, 2001, 103, 207-212.
15. Okopieñ B, Cwalina L, Łebek M, Kowalski J, Zielinski M, Wisniewska-Wanat M, Kalina Z et al.: Effects of fibrates on plasma prothrombotic activity in patients with type IIb dyslipidemia. Int J Clin Pharmacol Ther, 2001, 39, 551-557.
16. Okopieñ B, Haberka M, Madej A, Belowski D, Łabuzek K, Krysiak R, Zieliñski M, Herman ZS: Extralipid effects of micronized fenofibrate in dyslipidemic patients. Pharmacol Rep, 2006, 58, 729-735.
17. Okopieñ B, Krysiak R, Herman ZS: Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance. J Clin Endocrinol Metab, 2006, 91, 1770-1778.
18. O'Neal DN, O'Brien RC, Timmins KL, Grieve GD, Lau KP, Nicholson GC, Kotowicz MA, Best JD: Gemfibrozil treatment increases low-density lipoprotein particle size in type 2 diabetes mellitus but does not alter in vitro oxidizability. Diabet Med, 1998, 15, 870-877.
19. Petersen JL, McGuire DK: Impaired glucose tolerance and impaired fasting glucose - a review of diagnosis, clinical implications and management. Diab Vasc Dis Res, 2005, 2, 9-15.
20. Pruski M, Krysiak R, Okopieñ B: Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia. Diabetes Care, 2009, 32, 1421-1424.
21. Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, Koenig Wet al.: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med, 2008, 359, 2195-2207.
22. Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, Faas FH, Anderson JW: Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med, 2002, 162, 2597-2604.
23. Sarwar N, Thompson AJ, Di Angelantonio E: Markers of inflammation and risk of coronary heart disease. Dis Markers, 2009, 26, 217-225.
24. Skrha J, Stulc T, Hilgertova J, Weiserova H, Kvasnicka J, Ceska R: Effect of simvastatin and fenofibrate on endothelium in type 2 diabetes. Eur J Pharmacol, 2004, 493, 183-189.
25. Soderberg S, Zimmet P, Tuomilehto J, de Courten M, Dowse GK, Chitson P, Stenlund H et al.: High incidence of type 2 diabetes and increasing conversion rates from impaired fasting glucose and impaired glucose tolerance to diabetes in Mauritius. J Intern Med, 2004, 256, 37-47. (Pubitemid 38813618)
26. Twigg SM, Kamp MC, Davis TM, Neylon EK, Flack JR; Australian Diabetes Society; Australian Diabetes Educators Association: Prediabetes: a position statement from the Australian Diabetes Society and Australian Diabetes Educators Association. Med J Aust, 2007, 186, 461-465.
27. Ushiroyama T, Ikeda A, Higashio S, Ueki M: Coagulofibrinolytic assessment of effects of bezafibrate on hypertriglyceridemia in postmenopausal women. Blood Coagul Fibrinolysis, 2004, 11, 709-714. (Pubitemid 32010204)